MIRM: Mirum Pharmaceuticals, Inc.
Performance
MIRM +36.81%
Watchlist
Select an item
Summary
MIRM at a glance
MIRM returned +36.81% over the past year and +41.74% a year over five years. Its worst drop in that year was -38.36%, smaller than 40% of stocks on Redstone, and its Sharpe ratio of 0.82 beats 67% of stocks on Redstone. It pays no dividends.
Current Drawdown
-27.53%
Rolling Volatility
57.11%
Actions
Metrics
Risk Indicators
Alpha28.84%
Beta1.10x
Sharpe0.82
Sortino1.15
Omega1.16
Calmar0.96
Martin2.29
Profile
About MIRM
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $6.1B
- Listed
- Jul 2019
- Employees
- 433
- Headquarters
- Foster City, CA
- Website
- mirumpharma.com
Comparisons